TIGIT: A potential immunotherapy target for gynecological cancers
Pathology - Research and Practice · 2024
DOI: 10.1016/j.prp.2024.155202 ↗Kurz gefasst
Übersichtsarbeit in der Zeitschrift Pathology - Research and Practice, 2024. Verfasst von Siyue Jiang und 2 weiteren Autor:innen. Beteiligte Einrichtung: The third People's Hospital of Suining, Suining, Sichuan, China. Hauptthemen laut MEDLINE: Receptors, Immunologic, Genital Neoplasms, Female. Die Arbeit wurde bisher 7-mal zitiert (Crossref) und nennt 88 Literaturangaben.
Abstract (Originalsprache)
Gynecological cancer represents a significant global health challenge, and conventional treatment modalities have demonstrated limited efficacy. However, recent investigations into immune checkpoint pathways have unveiled promising opportunities for enhancing the prognosis of patients with cancer. Among these pathways, TIGIT has surfaced as a compelling candidate owing to its capacity to augment the immune function of NK and T cells through blockade, thereby yielding improved anti-tumor effects and prolonged patient survival. Global clinical trials exploring TIGIT blockade therapy have yielded promising preliminary findings. Nevertheless, further research is imperative to comprehensively grasp the potential of TIGIT-based immunotherapy in optimizing therapeutic outcomes for gynecological cancers. This review primarily delineates the regulatory network and immunosuppressive mechanism of TIGIT, expounds upon its expression and therapeutic potential in three major gynecological cancers, and synthesizes the clinical trials of TIGIT-based cancer immunotherapy. Such insights aim to furnish novel perspectives and serve as reference points for subsequent research and clinical application targeting TIGIT in gynecological cancers.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- The third People's Hospital of Suining, Suining, Sichuan, China.
- First Clinical Medical College of Lanzhou University, Lanzhou, Gansu, China.
- Department of Obstetrics and Gynecology, First Hospital of Lanzhou University, Key Laboratory of Gynecologic Oncology Gansu Province, Lanzhou, Gansu, China. Electronic address: yxyanglzu@163.com.
Zitieren
APA
Jiang, S., Wang, W., & Yang, Y. (2024). TIGIT: A potential immunotherapy target for gynecological cancers. Pathology - Research and Practice. https://doi.org/10.1016/j.prp.2024.155202
Vancouver
Jiang S, Wang W, Yang Y. TIGIT: A potential immunotherapy target for gynecological cancers. Pathology - Research and Practice. 2024. doi:10.1016/j.prp.2024.155202
BibTeX
@article{Jiang2024,
author = {Jiang, Siyue and Wang, Wenhua and Yang, Yongxiu},
title = {TIGIT: A potential immunotherapy target for gynecological cancers},
journal = {Pathology - Research and Practice},
year = {2024},
doi = {10.1016/j.prp.2024.155202}
}
EUVIMED